Prime Med­i­cine show­cas­es its first in vi­vo edit­ing da­ta in mon­keys and mice

Prime Med­i­cine, a biotech com­pa­ny de­vel­op­ing a new class of gene ed­i­tors that promis­es to make near­ly any change to any gene, said the first tests of its tech­nol­o­gy in an­i­mals were suc­cess­ful, paving the way to hu­man stud­ies.

One of the com­pa­ny’s ex­per­i­men­tal treat­ments is for a rare liv­er con­di­tion called glyco­gen stor­age dis­ease Ib (GS­DIb). When de­liv­ered via lipid nanopar­ti­cle in­fu­sion, the in vi­vo ther­a­py edit­ed up to 50% of liv­er cells in mon­keys and up to 56% of liv­er cells in mice — far more than the es­ti­mat­ed 10% edit­ing need­ed for a ther­a­peu­tic ef­fect.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.